Appendix A: Errata. Hematology Am Soc Hematol Educ Program 2006; 2006 (1): 503. doi: https://doi.org/10.1182/asheducation-2006.1.503
Download citation file:
Erratum for Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology (Am Soc Hematol Educ Program). 2005:267–277.
Page 273. Table 3T1 . Several columns were misaligned and some information had been omitted. Please replace with the following table:
Selected studies in the last 5 years evaluating the outcome of peripheral T-cell lymphoma (PTCL) patients who have received high dose chemotherapy and autologous (auto) or allogeneic (allo) stem cell transplant in first remission or with relapsed refractory disease.
| Study . | Total No. Pts . | PTCL Subtype (n) . | First Remission or Relapsed/Refractory (n) . | EFS/PFS . | OS . | Comments . |
|---|---|---|---|---|---|---|
| Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma (ALK positive (+) and negative (−); CUTALCL, cutaneous ALCL; EFS, event-free survival; ETTL, enteropathy-associated T-cell lymphoma; PFS, progression-free survival; OS, overall survival; PR, partial remission; PTCLUS, peripheral T-cell lymphoma, unspecified; Auto, high-dose chemotherapy and autologous stem cell transplant; allo, allogeneic transplant; RIC, reduced intensity conditioning | ||||||
| Rodriguez38 | 115 | PTCLUS (80) ALCL (25) AILT (6) Other (2) | First remission (37) Auto Relapsed/refractory (78) Auto | 79% (5 y) 79% (5 y) 39% (5 y) | 80% (5 y) 80% (5 y) 45% (5 y) | ALK status unknown; median age 31 for primary transplant No patient salvaged with refractory disease |
| Jagasia43 | 28 | PTCLUS (6) ALCL (11) ALK positive (7) ALK negative (4) CUTALCL (5) AILT (3) NK/T (3) | Relapsed/refractory Auto (23) Allo (5) | 50% (3 y) Non-ALCL 38% (3 y) ALK+ ALCL 100% (3 y) ALK– ALCL 0% (3 y) | 43% (6 y) Non-ALCL 47% (3 y) ALK+ ALCL 100% (3 y) ALK– ALCL 50% (3 y) | Outcome analyses combined auto and allo transplants ALK+ ALCL superior outcome to other PTCLs and DLBCL |
| Blystad39 | 40 | PTCLUS(20) ALCL (14) AILT (2) ETTL (2) NK/T (2) | First remission (17) Auto Relapsed (23) Auto | 48% (3 y) | 58% (3 y) Non-ALCL 44% (3 y) ALCL 79% (3 y) | Outcome analyses combined first remission and relapsed groups ALK status unknown |
| Song44 | 36 | PTCLUS (20) ALCL (9) AILT (2) NK/T (4) ETTL (1) | Relapsed/refractory Auto | 37% (3 y) PTCLUS 23% (3 y) ALCL 67% (3 y) | 48% (3 y) PTCLUS 35% (3 y) ALCL 78% (3 y) | ALCL (ALK status unknown) trend to improved outcome compared with PTCLUS and DLBCL |
| Corradini47 | 17 | PTCLUS (9) ALK– ALCL (4) AILT (4) | Relapsed/refractory RIC Allo | 64% (3 y) | 81% (3 y) | Many had late relapses Unknown whether primary CUTALCL were included |
| Study . | Total No. Pts . | PTCL Subtype (n) . | First Remission or Relapsed/Refractory (n) . | EFS/PFS . | OS . | Comments . |
|---|---|---|---|---|---|---|
| Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma (ALK positive (+) and negative (−); CUTALCL, cutaneous ALCL; EFS, event-free survival; ETTL, enteropathy-associated T-cell lymphoma; PFS, progression-free survival; OS, overall survival; PR, partial remission; PTCLUS, peripheral T-cell lymphoma, unspecified; Auto, high-dose chemotherapy and autologous stem cell transplant; allo, allogeneic transplant; RIC, reduced intensity conditioning | ||||||
| Rodriguez38 | 115 | PTCLUS (80) ALCL (25) AILT (6) Other (2) | First remission (37) Auto Relapsed/refractory (78) Auto | 79% (5 y) 79% (5 y) 39% (5 y) | 80% (5 y) 80% (5 y) 45% (5 y) | ALK status unknown; median age 31 for primary transplant No patient salvaged with refractory disease |
| Jagasia43 | 28 | PTCLUS (6) ALCL (11) ALK positive (7) ALK negative (4) CUTALCL (5) AILT (3) NK/T (3) | Relapsed/refractory Auto (23) Allo (5) | 50% (3 y) Non-ALCL 38% (3 y) ALK+ ALCL 100% (3 y) ALK– ALCL 0% (3 y) | 43% (6 y) Non-ALCL 47% (3 y) ALK+ ALCL 100% (3 y) ALK– ALCL 50% (3 y) | Outcome analyses combined auto and allo transplants ALK+ ALCL superior outcome to other PTCLs and DLBCL |
| Blystad39 | 40 | PTCLUS(20) ALCL (14) AILT (2) ETTL (2) NK/T (2) | First remission (17) Auto Relapsed (23) Auto | 48% (3 y) | 58% (3 y) Non-ALCL 44% (3 y) ALCL 79% (3 y) | Outcome analyses combined first remission and relapsed groups ALK status unknown |
| Song44 | 36 | PTCLUS (20) ALCL (9) AILT (2) NK/T (4) ETTL (1) | Relapsed/refractory Auto | 37% (3 y) PTCLUS 23% (3 y) ALCL 67% (3 y) | 48% (3 y) PTCLUS 35% (3 y) ALCL 78% (3 y) | ALCL (ALK status unknown) trend to improved outcome compared with PTCLUS and DLBCL |
| Corradini47 | 17 | PTCLUS (9) ALK– ALCL (4) AILT (4) | Relapsed/refractory RIC Allo | 64% (3 y) | 81% (3 y) | Many had late relapses Unknown whether primary CUTALCL were included |
